The Company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms.
The Company s main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington s disease, acute ischemic stroke, acute inflammatory indications and other diseases.
HISTORY
The Company was established on December 18, 2007.
The Company was listed on PUBLIC COMPANIES on December 5, 2023.
The Company was listed on EMERGING STOCKS on March 11, 2024.
总部
No.16,Wenhu St, Neihu Dist
台北市; 台北市;
联系方式: 购买Steminent Biotherapeutics Inc.报告以查看信息。
EMIS公司简介是一个更大的信息服务的一部分，它结合了公司，行业和国家数据和分析在超过125个新兴市场.
请求EMIS服务的演示查看更多信息, 申请试用